By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


PharmaMar S.A. 

Pol Ind. la Mina Avenida de los Reyes, 1

Colmenar Viejo  Madrid  28770  Spain
Phone: 34-91-8466000 Fax: 34-91-8466001


Company News
PharmaMar Completes The Patient Recruitment For The "CORAIL" Phase III Pivotal Study With PM1183 10/18/2016 11:57:44 AM
PharmaMar Announces Positive Results From Its Phase II Study With Lurbinectedin In BRCA 1/2 - Associated Metastatic Breast Cancer At The ESMO 2016 Congress 10/10/2016 8:36:47 AM
PharmaMar Shows New Clinical Data On Yondelis And Lurbinectedin At ESMO 2016 10/6/2016 9:43:41 AM
PharmaMar And Boryung Pharmaceuticals Co., Ltd. Sign A Licensing Agreement For Aplidin (Plitidepsin) In Korea 10/4/2016 7:37:55 AM
PharmaMar Submits MAA To EMA For Aplidin For The Treatment Of Multiple Myeloma 9/22/2016 8:16:45 AM
PharmaMar Announces The IDMC´s Response On The CORAIL Trial Using PM1183 8/11/2016 12:14:46 PM
PharmaMar S.A. Initiates A Pivotal Phase III ATLANTIS Study With PM1183 In Combination With Doxorubicin In Patients With Small Cell Lung Cancer 8/2/2016 7:24:27 AM
PharmaMar S.A. Announces The Start Of A Pivotal Study With Plitidepsin In Angioimmunoblastic T-Cell Lymphoma 6/15/2016 11:08:45 AM
PharmaMar S.A. Release: The Phase III Clinical Trial Using PM1183 In Treating Ovarian Cancer (CORAIL) Continues Following The IDMC's Positive Recommendation 2/8/2016 8:53:06 AM
PharmaMar S.A. And Specialised Therapeutics Asia Sign Licensing And Marketing Agreement For APLIDIN (plitidepsin) Covering Several Asian Countries 2/2/2016 7:45:44 AM